



**THE FOUNDATION  
FOR SECURE  
MARKETS**

#50929

**Date:** August 25, 2022

**Subject:** Soleno Therapeutics, Inc. - Reverse Split  
Option Symbol: SLNO  
New Symbol: SLNO1  
Date: 8/26/22

Soleno Therapeutics, Inc. (SLNO) has announced a 1-for-15 reverse stock split. As a result of the reverse stock split, each SLNO Common Share will be converted into the right to receive approximately 0.066667 (New) Soleno Therapeutics, Inc. Common Shares. The reverse stock split will become effective before the market open on August 26, 2022. The treatment of fractional shares is not yet confirmed.

**Contract Adjustment**

**Effective Date:** August 26, 2022

**Option Symbol:** SLNO changes to SLNO1

**Contract Multiplier:** 1

**Strike Divisor:** 1

**New Multiplier:** 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

**New Deliverable Per Contract:**

- 1) Approximately 6 (New) Soleno Therapeutics, Inc. (SLNO) Common Shares (subject to delayed settlement until treatment of fractional shares is confirmed)
- 2) Cash in lieu of approximately 0.6667 fractional shares, if any

Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

**CUSIP:** SLNO (New): 834203309

**Pricing**

Until the number of SLNO shares and the cash in lieu amount of fractional shares, if any, are determined, the underlying price for SLNO1 will be determined as follows:

SLNO1 = 0.066667 (SLNO)

### **Delayed Settlement**

OCC will delay settlement of the SLNO component and the cash portion of the SLNO1 deliverable until the number of SLNO shares and cash in lieu of fractional SLNO Shares is determined. Upon determination of the number of SLNO shares and cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate number of SLNO shares and the appropriate cash amount.

### **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).